Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M76.8Revenue $M0.3Net Margin (%)--Altman Z-Score1.5
Enterprise Value $M54.7EPS $-0.2Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.5Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %-4.1Quick Ratio7.2Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-6.4Current Ratio7.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-76.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-92.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M110ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONCY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONCYFirst Eagle Investment 2014-09-30 Sold Out $0.563 - $1.66
($1.28)
$ 0.70-45%Sold Out0
ONCYFirst Eagle Investment 2014-06-30 Reduce$1.23 - $1.99
($1.43)
$ 0.70-51%Reduce 55.85%188,600
ONCYFirst Eagle Investment 2013-03-31 Buy $2.99 - $4.67
($3.6)
$ 0.70-81%New holding450,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONCY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dillahunty, Mary AnnSenior Officer 2014-11-13Sell1,201$0.6114.75 view
Hohol, Linda Margaret OwerriDirector 2014-10-20Buy10,000$0.5625 view
Levy, EdwinDirector 2014-10-03Buy16,000$0.6212.9 view
Thompson, BradleyDirector, Senior Officer 2014-10-03Buy10,000$0.6114.75 view
Dinning, James FrancisDirector 2014-10-03Buy10,000$0.6114.75 view
Dinning, James FrancisDirector 2014-10-02Buy20,000$0.616.67 view
Hohol, Linda Margaret OwerriDirector 2014-08-12Buy6,800$1.51-53.64 view
Dinning, James FrancisDirector 2014-07-04Buy15,000$1.45-51.72 view
Levy, EdwinDirector 2014-01-03Buy5,900$1.72-59.3 view
Dinning, James FrancisDirector 2013-12-13Buy5,000$1.62-56.79 view

Press Releases about ONCY :

    Quarterly/Annual Reports about ONCY:

      News about ONCY:

      Articles On GuruFocus.com
      No related article found.

      More From Other Websites
      Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
      Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
      Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
      Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
      Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
      Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
      Oncolytics' Reolysin Gets Another Orphan Drug Status in EU - Analyst Blog May 01 2015
      Nasdaq stocks posting largest volume increases Apr 29 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
      Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
      Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
      Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
      Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
      Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog Apr 20 2015
      Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual... Apr 20 2015
      Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual... Apr 20 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK